Biontech Se ADR (BNTX)

$101.59 4.26 (4.02%)

16:24 EST BNTX Stock Quote Delayed 30 Minutes

Volume:

Previous Close -

Market Cap -

PE Ratio -

EPS -

Volume (Avg. Vol.) 2.86M

Day's Range 97.31 - 104.99

52-Week Range 28.00 - 131.00

Dividend & Yield N/A (N/A)

BNTX Stock Predictions, Articles, and Biontech Se ADR News

From InvestorPlace
From the Web

7 Biotech Stocks To Buy Beyond Covid Vaccine Plays

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Dec 14, 2020

It’s a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

The Question to Ask About COVID-19 Vaccine Stocks

By Eric Fry, Editor, Fry's Investment Report Dec 10, 2020

The time to pick your horse in the vaccine race was months ago. These stocks were much cheaper before their trials started. Here's where to focus instead.

The 7 Best Coronavirus Vaccine Stocks Still In The Race For A Cure

By Tezcan Gecgil, InvestorPlace Contributor Dec 8, 2020

Buying strong vaccine stocks at the forefront of the scientific race to treat Covid-19 will help any long-term portfolio in 2021.

How to Invest in a Post-COVID World

By Matt McCall, Editor, MoneyWire Nov 25, 2020

Buying stocks that have been hit by a serious but solvable problem, can lead to extraordinary gains when things work out positively.

With Pfizer Partnership, BioNTech Stock Should Push Higher

By Louis Navellier and the InvestorPlace Research Staff, Editor, Growth Investor Nov 23, 2020

In light of a collaboration with a major drugmaker and a fast-track toward possible FDA approval, BNTX stock is practically irresistible.

Blockchain: How This Next Great Tech Platform Could Help Fight COVID-19

By Matt McCall, Editor, MoneyWire Nov 21, 2020

Simply put, blockchain is the safest way to store and transfer information ever created, which makes it ideal for tracking vaccines.

Covid Vaccine Update: How Do the Moderna and Pfizer Coronavirus Vaccines Compare?

By Sarah Smith, InvestorPlace Web Content Producer Nov 18, 2020

With a new Covid vaccine update today, how do the Moderna and Pfizer coronavirus vaccines compare? Dive in here.

4 Stocks to Buy That Reported Stellar Earnings

By Faisal Humayun Nov 17, 2020

The earnings season has been mixed. These four stocks to buy reported strong earnings and are likely to be out-performers.

Where to Invest Before the Holiday Season

By Louis Navellier, Editor, Growth Investor Nov 13, 2020

We’re heading into the seasonally strong time of year, and as Thanksgiving week approaches, it is likely the market will take off. So, if you have any cash to invest, please be invested before Thanksgiving!

5 Companies to Invest in for 2021 as Markets Price in Economy’s Prospects

By Ian Cooper Nov 13, 2020

After the volatility of 2020, analysts see some calm in the offing. Here are 5 companies to invest in on those prospects.

BioNTech News: 5 Things for BNTX Stock Investors to Know

By Nick Clarkson, Web Editor Nov 9, 2020

Shares of BNTX stock are flying on Monday after BioNTech and Pfizer announced extremely positive results from their Covid-19 vaccine trials.

Vaccine News: Pfizer Stock Soars 15% on Coronavirus Trial Results

By Sarah Smith, InvestorPlace Web Content Producer Nov 9, 2020

Pfizer stock is rallying higher Monday on coronavirus vaccine results, and it's taking the rest of the stock market with it.

Avoid Inovio Pharmaceuticals Stock Until the FDA Greenlights Trials

By Ian Cooper Oct 30, 2020

While I’d like to tell you Inovio Pharmaceuticals is a blood-in-the-streets opportunity, I can’t. Avoid INO stock for now.

BioNTech Investor Fortunes Rise and Fall on Headlines, Pacts and Funding

By Tezcan Gecgil, InvestorPlace Contributor Sep 18, 2020

BNTX stock is a high-risk high-return investment. BioNTech shares will likely to range-trade in the short run.

Pfizer Stock Pops on Vaccine Timeline News, Trial Expansion

By Sarah Smith, InvestorPlace Web Content Producer Sep 14, 2020

Pfizer stock and partner BioNTech are rallying Monday morning on news the two companies could vaccinate Americans before the end of 2020.

Why Novavax Stock is Still a Strong Buy Even After an 800% Move

By Ian Cooper Jul 27, 2020

While NVAX stock could race higher on news in coming days of its clinical trials results, play this one safe with a trailing stop loss to safeguard any wins you have to date.

4 Catalysts Could Drive Inovio Pharmaceuticals Stock to Near-term Highs

By Ian Cooper Jul 22, 2020

Inovio Pharmaceuticals remains one of the most undervalued of the vaccine makers. Even after a 455% run higher, INO stock has plenty of upside fueled by plenty of catalysts.